Abstract
CDK4/6 inhibitor, ribociclib in combination with an aromatase inhibitor (AI) was first approved for post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (ABC). In 2018, ribociclib received expanded indication as first-line (1L) therapy in combination with AI for pre/peri-menopausal women and in combination with fulvestrant for post-menopausal women. A 3-year budget impact analysis from a US third-party commercial or Medicare payer perspective was developed to estimate the financial impact associated with ribociclib indication expansion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
